Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $384.00 at Jefferies Financial Group

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) had its price objective hoisted by equities research analysts at Jefferies Financial Group from $328.00 to $384.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm presently has a "buy" rating on the biopharmaceutical company's stock. Jefferies Financial Group's price target would suggest a potential upside of 18.19% from the stock's current price.

Several other brokerages have also recently commented on ALNY. HC Wainwright restated a "buy" rating and issued a $500.00 target price on shares of Alnylam Pharmaceuticals in a research report on Wednesday, April 2nd. BMO Capital Markets boosted their target price on shares of Alnylam Pharmaceuticals from $300.00 to $360.00 and gave the company an "outperform" rating in a research report on Tuesday, June 24th. Wells Fargo & Company boosted their target price on shares of Alnylam Pharmaceuticals from $287.00 to $333.00 and gave the company an "equal weight" rating in a research report on Monday, June 30th. Bank of America boosted their target price on shares of Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the company a "buy" rating in a research report on Friday, March 21st. Finally, Wall Street Zen upgraded shares of Alnylam Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and twenty-two have assigned a buy rating to the company. Based on data from MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $341.91.

Alnylam Pharmaceuticals Stock Performance

Alnylam Pharmaceuticals stock traded up $0.78 during midday trading on Monday, hitting $324.91. The company's stock had a trading volume of 348,823 shares, compared to its average volume of 854,456. Alnylam Pharmaceuticals has a 1-year low of $205.87 and a 1-year high of $333.70. The company has a debt-to-equity ratio of 8.88, a current ratio of 3.04 and a quick ratio of 2.98. The company has a 50-day moving average price of $296.35 and a two-hundred day moving average price of $267.00. The company has a market cap of $42.37 billion, a price-to-earnings ratio of -155.46 and a beta of 0.23.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.07). Alnylam Pharmaceuticals had a negative return on equity of 510.31% and a negative net margin of 11.49%. The business had revenue of $594.19 million during the quarter, compared to analyst estimates of $584.32 million. During the same quarter last year, the firm earned ($0.16) EPS. Alnylam Pharmaceuticals's revenue for the quarter was up 20.2% compared to the same quarter last year. As a group, sell-side analysts predict that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current year.

Insider Transactions at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 31,640 shares of the company's stock in a transaction on Friday, May 30th. The shares were sold at an average price of $304.39, for a total value of $9,630,899.60. Following the sale, the chief executive officer directly owned 48,948 shares of the company's stock, valued at approximately $14,899,281.72. This represents a 39.26% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 1.20% of the company's stock.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Larson Financial Group LLC boosted its stake in shares of Alnylam Pharmaceuticals by 187.2% in the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 73 shares during the last quarter. SVB Wealth LLC bought a new stake in shares of Alnylam Pharmaceuticals in the 1st quarter valued at $27,000. Park Square Financial Group LLC bought a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter valued at $28,000. Whipplewood Advisors LLC boosted its stake in shares of Alnylam Pharmaceuticals by 208.8% in the 1st quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 71 shares during the last quarter. Finally, Bessemer Group Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 176.9% in the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 69 shares during the last quarter. 92.97% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.